206 related articles for article (PubMed ID: 30269331)
21. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia.
Oka S; Ono K; Nohgawa M
Anticancer Drugs; 2020 Jun; 31(5):536-539. PubMed ID: 31934889
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome.
Corbin ZA; Nguyen-Lin A; Li S; Rahbar Z; Tavallaee M; Vogel H; Salva KA; Wood GS; Kim YH; Nagpal S
J Neurooncol; 2017 May; 132(3):439-446. PubMed ID: 28271282
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada.
Elsea D; Savage KJ; Lilley C; Lisano J; Liu J; Yu KS
Adv Ther; 2023 May; 40(5):2326-2338. PubMed ID: 36920744
[TBL] [Abstract][Full Text] [Related]
25. Brentuximab vedotin: unexpectedly good response in CD30
Sun J; Wang Y
Br J Dermatol; 2019 Jun; 180(6):1300-1301. PubMed ID: 31157447
[No Abstract] [Full Text] [Related]
26. [Ulceration of lymphomatous skin lesions in a patient with Sezary syndrome treated with brentuximab-vedotin].
Maitrepierre F; Schissler C; Cribier B; Lipsker D
Ann Dermatol Venereol; 2020 Mar; 147(3):198-201. PubMed ID: 31959414
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic hematopoietic stem cell transplantation in mycosis fungoides.
Atalla A; Hallack Neto AE; Siqueira DB; Toledo GC
An Bras Dermatol; 2013; 88(6 Suppl 1):216-9. PubMed ID: 24346924
[TBL] [Abstract][Full Text] [Related]
28. Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment.
Cerroni L
Semin Cutan Med Surg; 2018 Mar; 37(1):2-10. PubMed ID: 29719014
[TBL] [Abstract][Full Text] [Related]
29. FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.
Richardson NC; Kasamon YL; Chen H; de Claro RA; Ye J; Blumenthal GM; Farrell AT; Pazdur R
Oncologist; 2019 May; 24(5):e180-e187. PubMed ID: 30914464
[TBL] [Abstract][Full Text] [Related]
30. Dermal xanthomatous infiltrates after brentuximab vedotin therapy in mycosis fungoides with large-cell transformation: A novel histologic finding.
Buchely N; Al-Rohil RN; Aung PP; Jour G; Torres-Cabala C; Prieto VG; Ivan D
J Cutan Pathol; 2018 May; ():. PubMed ID: 29806104
[TBL] [Abstract][Full Text] [Related]
31. Tumor-stage mycosis fungoides in palmoplantar localization with large-cell transformation and partial CD30 expression shows complete response to brentuximab vedotin.
Pham AK; Carter JB; Ratcliffe NR; Fuld AD; Lansigan F; Burnside NJ; Guill MA; Zug KA; Jarvis LA; LeBlanc RE
J Cutan Pathol; 2018 Jun; 45(6):458-462. PubMed ID: 29512830
[TBL] [Abstract][Full Text] [Related]
32. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.
Dummer R; Prince HM; Whittaker S; Horwitz SM; Kim YH; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown L; Sanches JA; Ortiz-Romero PL; Akilov OE; Geskin L; Huen A; Walewski J; Wang Y; Lisano J; Richhariya A; Feliciano J; Zhu Y; Bunn V; Little M; Zagadailov E; Dalal MR; Duvic M
Eur J Cancer; 2020 Jul; 133():120-130. PubMed ID: 32502876
[TBL] [Abstract][Full Text] [Related]
33. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
Mediwake H; Morris K; Curley C; Butler J; Kennedy G
Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
[TBL] [Abstract][Full Text] [Related]
34. Safety and effectiveness of the combination of systemic gemcitabine and intralesional brentuximab vedotin in tumor-stage mycosis fungoides.
Torre-Castro J; Recio-Monescillo M; Castillo Bazan E; Díaz de la Pinta J; Rodríguez Pinilla M; Requena L; Córdoba R
Int J Dermatol; 2024 Jun; 63(6):828-830. PubMed ID: 38419393
[No Abstract] [Full Text] [Related]
35. [Treatment of mycosis fungoides and Sézary syndrome].
Nicolay JP; Assaf C
Hautarzt; 2017 Sep; 68(9):702-710. PubMed ID: 28770285
[TBL] [Abstract][Full Text] [Related]
36. Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post-transplantation.
Koh KN; Im HJ; Suh JK; Lee SW; Choi ES; Seo JJ
Pediatr Blood Cancer; 2015 Jun; 62(6):1063-5. PubMed ID: 25641881
[TBL] [Abstract][Full Text] [Related]
37. Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction.
Hofer V; Maurus K; Houben R; Schrama D; Roth S; Goebeler M; Geissinger E; Rosenwald A; Wobser M
J Cutan Pathol; 2022 Mar; 49(3):314-317. PubMed ID: 34854114
[No Abstract] [Full Text] [Related]
38. Cutaneous T-cell lymphomas-An update 2021.
Kempf W; Mitteldorf C
Hematol Oncol; 2021 Jun; 39 Suppl 1():46-51. PubMed ID: 34105822
[TBL] [Abstract][Full Text] [Related]
39. Long-term Remission by Brentuximab Vedotin for Non-mediastinal Gray Zone Lymphoma Refractory to Autologous Stem Cell Transplantation.
Ebisawa K; Masamoto Y; Koya J; Shimura A; Shinozaki-Ushiku A; Toyama K; Nakazaki K; Kurokawa M
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e602-e604. PubMed ID: 31551171
[No Abstract] [Full Text] [Related]
40. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]